Research programme: S6 kinase antagonists - HotSpot Therapeutics
Alternative Names: Ribosomal s6 kinase antagonists - HotSpot TherapeuticsLatest Information Update: 28 Sep 2023
At a glance
- Originator HotSpot Therapeutics
- Class Small molecules
- Mechanism of Action Ribosomal protein S6 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Metabolic disorders
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Metabolic-disorders in USA
- 09 Feb 2021 Research programme: S6 kinase antagonists - HotSpot Therapeutics is available for licensing as of 09 Feb 2021. https://www.hotspotthera.com/